Citadel Advisors’s PTC Therapeutics PTCT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $743K | Buy |
10,900
+3,300
| +43% | +$234K | ﹤0.01% | 8380 |
|
|
2025
Q4 | $577K | Sell |
7,600
-900
| -11% | -$65.4K | ﹤0.01% | 8684 |
|
|
2025
Q3 | $522K | Sell |
8,500
-3,600
| -30% | -$188K | ﹤0.01% | 9025 |
|
|
2025
Q2 | $591K | Buy |
12,100
+3,500
| +41% | +$166K | ﹤0.01% | 8249 |
|
|
2025
Q1 | $438K | Buy |
8,600
+3,400
| +65% | +$170K | ﹤0.01% | 8768 |
|
|
2024
Q4 | $235K | Sell |
5,200
-500
| -9% | -$21.4K | ﹤0.01% | 10150 |
|
|
2024
Q3 | $211K | Buy |
5,700
+1,000
| +21% | +$33.5K | ﹤0.01% | 10030 |
|
|
2024
Q2 | $144K | Sell |
4,700
-1,500
| -24% | -$48.6K | ﹤0.01% | 10404 |
|
|
2024
Q1 | $180K | Sell |
6,200
-1,900
| -23% | -$53.2K | ﹤0.01% | 10485 |
|
|
2023
Q4 | $223K | Buy |
8,100
+1,100
| +16% | +$25.2K | ﹤0.01% | 9724 |
|
|
2023
Q3 | $157K | Sell |
7,000
-300
| -4% | -$11.2K | ﹤0.01% | 10289 |
|
|
2023
Q2 | $297K | Sell |
7,300
-18,700
| -72% | -$915K | ﹤0.01% | 9076 |
|
|
2023
Q1 | $1.26M | Buy |
26,000
+23,500
| +940% | +$1.07M | ﹤0.01% | 6294 |
|
|
2022
Q4 | $95.4K | Sell |
2,500
-102,800
| -98% | -$4.27M | ﹤0.01% | 11286 |
|
|
2022
Q3 | $5.29M | Sell |
105,300
-20,300
| -16% | -$995K | ﹤0.01% | 3766 |
|
|
2022
Q2 | $5.03M | Buy |
+125,600
| New | +$4.4M | ﹤0.01% | 3780 |
|
|
2022
Q1 | – | Sell |
-8,500
| Closed | -$339K | – | 14378 |
|
|
2021
Q4 | $339K | Buy |
+8,500
| New | +$325K | ﹤0.01% | 10655 |
|
|
2021
Q2 | – | Sell |
-5,200
| Closed | -$246K | – | 14261 |
|
|
2021
Q1 | $246K | Buy |
5,200
+1,100
| +27% | +$65.3K | ﹤0.01% | 11270 |
|
|
2020
Q4 | $250K | Sell |
4,100
-7,200
| -64% | -$424K | ﹤0.01% | 9395 |
|
|
2020
Q3 | $528K | Buy |
11,300
+6,500
| +135% | +$320K | ﹤0.01% | 7203 |
|
|
2020
Q2 | $244K | Sell |
4,800
-14,600
| -75% | -$717K | ﹤0.01% | 8249 |
|
|
2020
Q1 | $865K | Buy |
19,400
+6,000
| +45% | +$302K | ﹤0.01% | 5587 |
|
|
2019
Q4 | $644K | Sell |
13,400
-3,300
| -20% | -$140K | ﹤0.01% | 6391 |
|
|
2019
Q3 | $565K | Sell |
16,700
-13,300
| -44% | -$579K | ﹤0.01% | 6544 |
|
|
2019
Q2 | $1.35M | Buy |
30,000
+15,100
| +101% | +$596K | ﹤0.01% | 5193 |
|
|
2019
Q1 | $561K | Sell |
14,900
-30,900
| -67% | -$1.04M | ﹤0.01% | 6609 |
|
|
2018
Q4 | $1.57M | Sell |
45,800
-29,800
| -39% | -$1.07M | ﹤0.01% | 4549 |
|
|
2018
Q3 | $3.55M | Buy |
75,600
+25,500
| +51% | +$1.06M | ﹤0.01% | 3473 |
|
|
2018
Q2 | $1.69M | Buy |
50,100
+20,200
| +68% | +$630K | ﹤0.01% | 4365 |
|
|
2018
Q1 | $809K | Sell |
29,900
-42,700
| -59% | -$1.08M | ﹤0.01% | 5126 |
|
|
2017
Q4 | $1.21M | Sell |
72,600
-36,100
| -33% | -$611K | ﹤0.01% | 4380 |
|
|
2017
Q3 | $2.17M | Buy |
108,700
+79,300
| +270% | +$1.55M | ﹤0.01% | 3317 |
|
|
2017
Q2 | $539K | Sell |
29,400
-800
| -3% | -$10.8K | ﹤0.01% | 5005 |
|
|
2017
Q1 | $297K | Buy |
30,200
+4,700
| +18% | +$56.9K | ﹤0.01% | 5895 |
|
|
2016
Q4 | $278K | Sell |
25,500
-9,400
| -27% | -$98.6K | ﹤0.01% | 5792 |
|
|
2016
Q3 | $489K | Buy |
34,900
+22,000
| +171% | +$179K | ﹤0.01% | 4898 |
|
|
2016
Q2 | $91K | Sell |
12,900
-11,200
| -46% | -$82.1K | ﹤0.01% | 6234 |
|
|
2016
Q1 | $155K | Sell |
24,100
-4,700
| -16% | -$81.6K | ﹤0.01% | 5808 |
|
|
2015
Q4 | $933K | Sell |
28,800
-337,800
| -92% | -$9.94M | ﹤0.01% | 3669 |
|
|
2015
Q3 | $9.79M | Buy |
366,600
+314,400
| +602% | +$13.4M | 0.01% | 1364 |
|
|
2015
Q2 | $2.51M | Buy |
52,200
+26,200
| +101% | +$1.53M | ﹤0.01% | 2794 |
|
|
2015
Q1 | $1.58M | Buy |
+26,000
| New | +$1.59M | ﹤0.01% | 3366 |
|
Other funds holding PTCT
RI
VPM
VCM
AC
Citadel Advisors's PTCT Position: Q1 2026 in Review
Citadel Advisors reduced its PTC Therapeutics (PTCT) stake by 67% in Q1 2026, selling an estimated $54.5M and leaving 385,199 shares worth $26.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1996.
Citadel Advisors first reported a position in PTCT in Q1 2014 and has held it in 44 quarters since. The position peaked at $106M in Q3 2025. 350 funds tracked by Wall St. Rank hold PTCT as of Q1 2026.
- Citadel Advisors held 385,199 shares of PTC Therapeutics worth $26.2M as of Q1 2026.
- Citadel Advisors sold 769,256 PTC Therapeutics shares in Q1 2026, an estimated $54.5M.
- PTC Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #1996 holding.
- Citadel Advisors first reported a position in PTC Therapeutics in Q1 2014 and has held it in 44 quarters since.
- Citadel Advisors's PTC Therapeutics position peaked at $106M in Q3 2025.
- 350 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.